VRNA SELL +++++VRNA stock run up is way overdone. Leave it to scumbag analysts to upgrade a stock only after a major run up where are these douchebags when the stocks are cheap? Pump n dump much? Purchased a total of 70 puts so far will add for each $1 share price increase until correction Shortby ShortSeller763
VRNA SELL++++ overboughtVRNA overbought on positive lung cancer results. These money losing pharma stocks always tend to overshoot. We should correct under $15 in coming days. Purchased 50 Feb 17th $20 puts. Will add for each $1 increase in share price.Shortby ShortSeller76Updated 442
VRNA Looking for a push above $12VRNA has some decent moves today during the first half of the day. The stock since the peak of the $14 zone has pulled back to the $9-$10 zone. Recently the stock was given an upgrade on Zacks for a strong buy which is always a good sentiment indicator from a business perspective. Could see another 10-20% move tomorrow? (Not financial advice) Recent News: www.fool.com ca.finance.yahoo.com ca.finance.yahoo.com by azheng26492
VRNA Three Falling Peaks (bearish)I found this pattern at tickeron website with the following data: STATUS = Confirmed CURRENT CONFIDENCE = 84% TARGET (EXIT) PRICE = 3.84 USD BREAKOUT (ENTRY) PRICE = 6.60 USD DISTANCE TO TARGET PRICE = 39.95% EMERGED ON = Aug 19, 12:00 PM (EDT) CONFIRMED ON = Sep 03, 01:03 PM (EDT) WITH CONFIDENCE LEVEL = 98% The Three Falling Peaks pattern forms when three minor Highs (1, 3, 5) arrange along a downward-sloping trend line. This pattern often emerges at the end of a rising trend, when a security slowly rolls over. It potentially indicates sellers moving in to replace buyers, which pushes the price lower. Trade idea If the price breaks out from the bottom pattern boundary, day traders and swing traders should trade with the DOWN trend. Consider selling the security short or buying a put option at the downward breakout price level. To identify an exit, compute the target price by subtracting the pattern’s height (maximum price minus minimum price within the pattern) from the breakout level the lowest low. When trading, wait for the confirmation move, which is when the price moves below the breakout level. To limit potential loss when price suddenly goes in the wrong direction, consider placing a stop order to buy back a short position or sell a put option at or above the breakout price.Shortby AlTorress112
200 Million in Oversubscribed Private Placement and SubscriptionVerona Pharma Raises $200 Million in Oversubscribed Private Placement and Subscription Funding to support Phase 3 ENHANCE clinical program in COPD The Financing comprises a private placement of 39,090,009 of the Company’s American Depositary Shares (“ADSs”), each representing eight ordinary shares of the Company (“Ordinary Shares”), at a price of $4.50 per ADS, and 43,111,112 of the Company’s Ordinary Shares at the equivalent price per Ordinary Share, being £0.45 or $0.5625 Verona Pharma intends to use the net proceeds from the Financing primarily to fund its Phase 3 clinical program ENHANCE (Ensifentrine as a Novel inHAled Nebulized COPD thErapy) in chronic obstructive pulmonary disease (COPD) and for general corporate purposes. The Phase 3 clinical trials are planned to start later in 2020. With this financing we plan to initiate our Phase 3 ENHANCE clinical trials later this year and expect to support our programs into 2023. www.veronapharma.com The treatment is different to anything currently out on the market for COPD in that it has a dual-action. Ensifentrine has not shown side effects such as nausea, vomiting and weight loss, that halted previous attempts to develop similar drugs. The market liked this strategy, alongside a good data package from the phases I and II of clinical trials. So highly regarded industry names such as RA Capital, one of America’s leading biotech investors, backed the phase III because they see potential for success. Even if you see more positive sentiment towards healthcare, it still depends on the quality of the individual companies. In this case Verona had a large data set, a clear path forward agreed with the regulator and clear inflexion points. www.proactiveinvestors.co.ukby AlenCiken3
LONG LIVEVerona Pharma Plc operates as a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for the treatment of respiratory diseases. hoping for bullish! Longby sayakagirl5